Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Changes in gene expression and targets for therapy.

M J Bussemakers1

  • 1Urology Research Laboratory, University Hospital, Nijmegen, The Netherlands. m.bussemakers@uro.azn.nl

European Urology
|May 15, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene.

The Journal of biological chemistry·2000
Same author

Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region.

Laboratory investigation; a journal of technical methods and pathology·2000
Same author

Cadherin switching in human prostate cancer progression.

Cancer research·2000
Same author

Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia.

European urology·2000
Same author

Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin.

Biochemical and biophysical research communications·2000
Same author

Complex cadherin expression in human prostate cancer cells.

International journal of cancer·2000
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
See all related articles

Identifying new genes like DD3, overexpressed in prostate cancer, offers potential for novel diagnostic and therapeutic strategies. Further research is crucial to determine their clinical utility in managing prostate cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Understanding molecular changes in prostate cancer is key for developing new diagnostic and therapeutic tools.
  • Critical biochemical pathways (angiogenesis, apoptosis, cell adhesion, signal transduction) offer therapeutic targets.
  • Tumor-specific antigens and gene promoters are vital for novel treatment modalities.

Purpose of the Study:

  • To explore molecular changes in prostate cancer for improved diagnostics and therapeutics.
  • To identify and characterize prostate cancer-specific genes as potential tumor markers and therapeutic targets.
  • To investigate the role of newly identified genes, such as DD3, in prostate cancer.

Main Methods:

  • Analysis of molecular changes in prostate cancer.

Related Experiment Videos

  • Identification and characterization of prostate-specific genes and antigens.
  • Gene expression studies, including DD3 overexpression in prostate cancer tissues.

    • Main Results:

    • Several molecular pathways and targets have been identified for therapeutic approaches.
    • New diagnostic and therapeutic tools are emerging, including prostate stem cell antigen.
    • The gene DD3 is significantly overexpressed in human prostate cancers and appears prostate-specific.

    Conclusions:

    • New prostate cancer-specific genes, like DD3, hold promise for improved diagnosis and treatment.
    • Further research is needed to validate the clinical usefulness of these genes for patient management.
    • Continued investigation into molecular alterations can lead to more effective prostate cancer therapies.